
ImmunoGen, Inc. (NASDAQ:IMGN) shares are trading flat at $3.57 after the company's Biologics License Application to treat ovarian cancer was accepted by the FDA with priority review.
ImmunoGen's BLA acceptance is for mirvetuximab soravtansine monotherapy in patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer who have been previously treated with 1 to 3 prior systemic treatments. The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of Nov. 28, 2022.